Maeda and coworkers, 2021: “Both young and older vaccinated individuals with good neutralization response would lose mRNA vaccine protection in 6 to 7 months after the 1st dose.”



Last update and review: August 7, 2021.

Contents hide

A short summary.

A noteworthy study from Japan by Maeda and coworkers, 2021 (1), shows that vaccine-elicited neutralizing activity of IgG antibodies is short-lived. After 6 to 7 months, antibody neutralizing activity is expected to be below the detection level. If vaccine-elicited antibody neutralizing activity is short, then other protective measures would be needed. The other protective measures that we recommend protect against a large majority of respiratory viruses and other pathogens. Our current view, as of August 2021, is that only for the most vulnerable individuals, the benefits of the current vaccines may outweigh the associated risks.

The study by Maeda and coworkers, 2021(1).

https://medical-en.nneandersphysiologicalliteracy.com/wp-content/uploads/2021/08/Maeda-and-coworkers-2021-Both-young-and-older-vaccinated-individuals-with-good-neutralization-response-would-lose-mRNA-vaccine-protection-in-6-to-7-months-after-the-1st-dose.

Important: “no correlation was seen between NT50s and (adverse effects) AEs”.

Maeda et al., 2021 (1):

BNT162b2-elicited immune response has no significant association with adverse effects.

Maeda-et-al-2021-BNT162b2-vaccine-elicited-immune-response-has-no-significant-association-with-adverse-effects. Only about 10% of vaccinated women did not have any adverse effects after the 2nd dose.

The average half-life of neutralizing activity in the vaccinees was approximately 67.8 days”.

Maeda et al., 2021 (1):

“The average half-life of neutralizing activity in the vaccinees was approximately 67.8 days and the average time length for their serums to lose the detectable neutralizing activity was 198.3 days. “While serums from elite-responders (NT 50 s>1,500-fold: the top 4% among all participants’ 18 NT 50 s) potently to moderately blocked the infectivity of variants of concerns, some serums with 19 moderate NT 50 s failed to block the infectivity of a beta strain.”

Interpretation by Maeda et coworkers, 2021(1).

BNT162b2-elicited immune response has no significant association with adverse effects (AEs).

BNT162b2-efficacy is likely diminished to under detection limit by 6-7 months post-1st shot.

High-level neutralizing antibody-containing serums potently to moderately block the infection of SARS-CoV-2 variants; however, a few moderate-level neutralizing antibody-containing serums failed to do so.

Our interpretation.

If vaccine-elicited immunity memory is short, other protective measures would be needed.

The list of the other protective measures that we recommend.

The measures listed below protect against a large majority of respiratory viruses and other pathogens : Literacy about respiratory viral infections, good nutritional status, Protection measures, hygiene, prophylactic measures, post-exposure prophylaxis, immediate treatment with a generic anti-viral treatment.

When neutralizing activity of IgG becomes undetectable 6-7 months after the first dose of Pfizer’s mRNA vaccine, there may be no protection of lungs.

Analysis: According to other publications, protection in lungs is mediated by IgG. If IgG-mediated neutralizing activity becomes undetectable at a point in time, there may be no protection against SARS-CoV-2 infection in lungs (lower respiratory ways).

Methods.

“The diluted serum-virus mixtures were inoculated to VeroE6 TMPRSS2 cells (1.0 x 10 4/well) in 96- 127 well plates.”

Maeda et al., 2021 (1):

“The neutralizing activity of serums from vaccinated individuals was determined by quantifying the serum-mediated suppression of the cytopathic effect (CPE) of each SARS-CoV-2 strain in VeroE6 TMPRSS2 cells as previously described with minor modifications 22. In brief, each serum was 4- 124 fold serially diluted in culture medium. The diluted sera were incubated with 50% tissue culture infectious dose (TCID 50) of viruses at 37°C for 20 min (final serum dilution range of 1:20 to 1:4000), after which the serum-virus mixtures were inoculated to VeroE6 TMPRSS2 cells (1.0 x 10 4/well) in 96- 127 well plates.” “After culturing the cells for 3 days, the levels of CPE observed in SARS-CoV-2-exposed cells were determined using the WST-8 assay employing Cell Counting Kit-8 (Dojindo, Kumamoto, Japan). The serum dilution that gave 50% inhibition of cytopathic effect (CPE) was defined as the 50% neutralization titer (NT 50). Each serum was tested in duplicate. Measurement of anti-SARS-CoV-2 antibody titers. Measurement of 3 anti-SARS-CoV-2 antibody levels (anti-S1-IgG, anti-S1-IgM, and anti-N-IgG) in each participant was performed using the chemiluminescence enzyme immunoassay (CLEIA) platform (HISCL) manufactured by Sysmex Co. (Kobe, Japan) as previously reported 24.”

A normal body temperature in Japanese is 36.89 degree Celsius.

Maeda et al., 2021 (1):

“As for participants with normal fever, their temperature was treated as 36.89 degree, a normal body temperature in Japanese 25.”

No significant difference in chronological decay rate of neutralizing antibodies was identified among the age subgroups.

Maeda et al., 2021 (1):

“We also asked whether the chronological decay rate of neutralization titers and S1-binding-IgG and -IgM differs among three age subgroups: (i) 20-39 yo, (ii) 40-59 yo, and (iii) 60’s and beyond. No significant difference was identified among the three age subgroups in the levels of neutralizing titers, IgG, or IgM levels (p=0.60, 0.16, and 0.11, respectively: Figures S3A-C).”

“The present data suggest that both young and older vaccinated individuals with good neutralization response would lose Pfizer’s mRNA vaccine protection in 6 to 7 months.”

Maeda et al., 2021 (1):

“The present data suggest that vaccinated individuals with good neutralization response would lose BNT162b2’s protection in 6 to 7 months without regard to age subgroups”

Terminology:

https://medical-en.nneandersphysiologicalliteracy.com/wp-content/uploads/2021/08/Maeda-and-coworkers-2021-Both-young-and-older-vaccinated-individuals-with-good-neutralization-response-would-lose-mRNA-vaccine-protection-in-6-to-7-months-after-the-1st-dose.

The authors of this paper and other authors use an awkwardly formulated term, “50% neutralizing titers (NT50). This term is difficult to understand to the readers and, often, to the authors themselves. Should be : titer neutralizing 50% of wells, 96 to 127 wells on a plate, inoculated with infectious virus. Let us assume that a plate contains 96 wells with Vero cells inoculated with a mixture of serum from vaccinated and replication-capable virions (see the “Methods” section above). If the serum at the used dilution neutralizes half of the 96 well, then we have “50% neutralizing titers” in that diluted serum.

Conclusions.

Our current view, as of August 2021, is that only for the most vulnerable individuals, the benefits of the current vaccines may outweigh the associated risks. The vulnerable are defined as those who can’t, for different reasons, take any other protection measure. We do NOT currently recommend ANY of the available COVID-19 vaccines to the generally competent normal people. The risks related to the currently available vaccines are very high. Chimerical adenovirus vector vaccines, mRNA vaccines, and deactivated virus vaccines against SARS-CoV-2 all contain elements that can provoke long-term inflammatory and autoimmune reactions, severe adverse effects, e.g. coagulopathy. Spike-protein of SARS-CoV-2 is not an inert particle. It is highly inflammatory and toxic. Viral mRNA can be integrated into human genome. And though several vaccines were effective in phase-3 trials by protecting against hospitalization, this protection turns out to be short-lived, limited to 2 to 7 months after vaccination. SARS-CoV-2 infection can be avoided rather easily, and it can be treated effectively by literate members of public. Be literate at all times.

Selected references.

1. Kenji Maeda1 , Masayuki Amano 2 , Yukari Uemura 3 , Kiyoto Tsuchiya 4 , Tomoko Matsushima 5 , Kenta Noda5 , Yo s u k e Sh imizu 3 , Asuka Fujiwara 1 , Yuki Takamatsu 1 , Yasuko Ichikawa 6 , Hidehiro Nishimura 6 , Mari Kinoshita 6 , Shota Matsumoto 6 , Hiroyuki Gatanaga 4 , Kazuhisa Yoshimura 7 , Shin-ichi Oka 4 , Ayako Mikami 3 , Wataru Sugiura 3 , Toshiyuki Sato 5 , Tomokazu Yo s h id a 5 , Shinya Shimada 6 , and Hiroaki Mitsuya. Correlates of Neutralizing/SARS-CoV-2-S1-binding Antibody Response with Adverse Effects and Immune Kinetics in BNT162b2-Vaccinated Individuals. A pre-print at available https://www.medrxiv.org/content/10.1101/2021.07.27.21261237v1 Accessed on August 5, 2021.



Leave a Reply